Acute myeloid leukaemia is a fatal disease for most patients. We have found that ferumoxytol (Feraheme), an FDA-approved iron oxide nanoparticle for iron deficiency treatment, demonstrates an anti-leukaemia effect in vitro and in vivo. Using leukaemia cell lines and primary acute myeloid leukaemia patient samples, we show that low expression of the iron exporter ferroportin results in a susceptibility of these cells via an increase in intracellular iron from ferumoxytol. The reactive oxygen species produced by free ferrous iron lead to increased oxidative stress and cell death. Ferumoxytol treatment results in a significant reduction of disease burden in a murine leukaemia model and patient-derived xenotransplants bearing leukaemia cells with low ferroportin expression. Our findings show how a clinical nanoparticle previously considered largely biologically inert could be rapidly incorporated into clinical trials for patients with leukaemia with low ferroportin levels.
A cute myeloid leukaemia (AML) is a heterogeneous blood cancer that results from an abnormal proliferation of white blood cells initiated and maintained by leukaemic stem cells (LSCs). AML is the most common type of acute leukaemia in adults, with poor survival rates for both adults and children and an overall five-year survival rate of 27-65% 1, 2 . Despite aggressive treatments that include bone marrow transplantation, most patients that achieve complete remission will relapse and ultimately die from their disease. Even though diverse chemotherapeutic agents have shown promise against AML, successful treatment has been hampered by (1) the low therapeutic index of chemotherapeutic drugs, (2) insufficient effect on quiescent cells such as LSCs, which give rise to and maintain the disease and (3) off-target effects 3 . Critical to the development of an effective therapy for AML is identifying unique key dysregulated mechanisms that can be used as therapeutic targets 4 . In AML, it has been increasingly acknowledged that LSCs are a major contributor for leukaemia chemoresistance and relapse 5 . Thus, therapies that selectively target LSCs without harming normal haematopoietic stem cells (HSCs) will improve outcomes and provide fewer systemic side effects.
AML treatment has relied on induction therapy, with the gold standard clinical practice being cytarabine arabinoside (ara-C) administered with an anthracycline. However, this and other therapies have not led to significant differences in overall survival or disease-free survival in the clinic 6 . In the preclinical space, parthenolide (PTL) and its derivatives have shown therapeutic promise as inhibitors of nuclear factor (NF)-κB for the elimination of LSCs LSCs are susceptible to PTL as they show constitutive activation of NF-κB compared to normal HSCs. PTL administration drives leukaemic cells into apoptosis via glutathione depletion. It shows a synergistic effect by sensitizing LSCs to drugs that generate reactive oxygen species (ROS), such as buthionine sulfoximine 8 . ROS can also be produced through the Fenton reaction when ferrous iron is present with peroxide and oxygen 9 . This ROS production is natively balanced by antioxidant production in combination with iron transport systems, such as transferrin internalization, storage by ferritin and iron export by ferroportin (FPN), the sole known cellular exporter of iron.
Regulation of FPN is well known from work on diseases related to iron storage, such as haemochromatosis. Importantly, FPN is the only known mammalian iron exporter, potentially serving as a bottleneck for iron efflux, with low FPN expression resulting in low iron efflux and higher iron retention. Recently, FPN has been found to be dysregulated in cancer, with more aggressive breast tumours being associated with low FPN expression. Other cancers, such as prostate, ovarian, colorectal and multiple myeloma, are also linked with low FPN expression relative to adjacent healthy tissues [10] [11] [12] [13] [14] [15] . This suggests that the degree of loss of FPN expression could have a potential diagnostic and prognostic value in several types of cancer. We thus sought to determine whether the levels of FPN expression in leukaemia cell lines and primary samples were indeed lower than in normal bone marrow. Here, we report that FPN also demonstrates significantly lower expression across leukaemic cell lines and primary AML samples including leukaemic blasts, CD34
+ progenitors and phenotypically defined LSCs compared to normal bone marrow CD34
+ progenitor cells (nBM CD34 + cells). We hypothesized that low levels of FPN would result in a susceptibility of leukaemia cells to induction of ROS through the Fenton reaction by exploiting the inability of the cells to export iron.
FDA-approved ferumoxytol displays antileukaemia efficacy against cells with low ferroportin levels
Vicenta Trujillo-Alonso 1, 7 , Edwin C. Pratt 2, 3, 7 , Hongliang Zong 1 Ferumoxytol, or Feraheme, is an iron oxide nanoparticle clinically available for the treatment of iron deficiency anaemia in patients in the USA 16 . Ferumoxytol has been widely considered to be safe when given as a single infusion. Ferumoxytol's iron core consists of 5,874 iron atoms, a mix of ferrous and ferric iron (Fe(ii) and Fe(iii)). In the Fenton reaction, both forms of iron, in the presence of peroxides, can produce harmful ROS as described previously 17 . We demonstrate that leukaemic cells and leukaemic stem/progenitor cells are sensitive to ROS generation from ferumoxytol in vitro and in vivo. We demonstrate that ferumoxytol inhibits disease progression in a highly aggressive acute leukaemia syngeneic mouse model (blast crisis CML, driven by the dual oncogenes BCR-ABL-NUP98-HOXA9) 18, 19 , where ara-C cannot target LSCs as effectively as the nanoparticle ferumoxytol. In addition, we also show that ferumoxytol selectively has an anti-leukaemic effect in AML patient-derived xenografts (PDX) expressing low levels of FPN. We propose that leukaemia cells with low FPN expression are vulnerable to ironbased oxidative stress and selectively sensitive to increases in ROS when administered as a nanoparticle. Importantly, normal tissue expresses higher FPN based on samples from cBioPortal 20 , providing a therapeutic window for ferumoxytol administration. Together, these data suggest the potential of targeting leukaemia cells characterized by low FPN expression with oxidative ferrotherapy by the administration of ferumoxytol.
Leukaemic blasts and stem cells are FPN-low
We and others have previously shown that leukaemia stem and progenitor cells are sensitive to ROS induction by small molecules 7, 21 . Because ROS can also be produced by ferrous iron through the Fenton reaction 9 , and ferroportin (FPN) is the sole known cellular iron exporter, we hypothesized that the absence of FPN could represent an Achilles heel for these cells. Thus, we sought to evaluate FPN expression in murine and human leukaemia cell lines. Using quantitative PCR with reverse transcription (qRT-PCR) we determined the messenger RNA (mRNA) expression of SLC40A1 (FPN) transcripts and found that basal FPN expression was decreased in the majority of leukaemia cell lines in comparison with normal bone marrow CD34
+ progenitor cells, with some lines showing nearly 10,000-fold lower expression ( Fig. 1a and Supplementary Table 1 ). Next, we evaluated primary AML samples, including purified CD34
+ progenitor cells, and found that the mRNA expression of FPN was decreased in AML blasts and CD34 + progenitor cells (Fig. 1b and Supplementary Table. 2). We also interrogated the FPN protein levels in leukaemia cell lines and AML patient samples using flow cytometry (Fig. 1c-e) . We found that most cell lines evaluated were low (16 out of 19) (Fig. 1d) . Importantly, in primary AML samples, we found that FPN protein levels were significantly lower in the progenitor (CD34 + ) and stem (CD34 + CD38 − ) cell populations compared to leukaemic blasts (Fig. 1e) . Together, FPN mRNA and protein expression in the majority of leukaemia cell lines and primary AML samples suggest a phenotype of aberrant iron export.
Based on the low FPN expression, we next hypothesized that FPN-low cells would retain more iron and thus demonstrate a higher vulnerability to ROS with increased cell death. Iron uptake, storage and excretion are well regulated, but administration of iron in the form of the nanoparticle ferumoxytol provides an alternative uptake route. We observed, by inductively coupled plasma mass spectrometry, a modest but significant increase in iron content per mg of protein for FPN-low but no significant difference in the intracellular iron content in FPN-high cells when they were treated for 24 h (Fig. 1f) . In addition, FPN-low cells showed a significant reduction in viability 48 h post-exposure to ferumoxytol with little to no effect on FPN-high cell lines (Fig. 1g) . Primary AML samples showed a similar effect at 24 h post exposure ( Supplementary Fig. 4 ). Human AML cell lines were found to all take up Cy5.5-labelled ferumoxytol at a high level (Supplementary Fig. 5a ) and were tested for the phagocytic marker CD68 to determine any difference in uptake. We found that all cells expressed the marker, suggesting that cell viability is not likely to be tied to the capacity of cells to phagocytize ( Supplementary Fig. 5b ). We next evaluated haem oxygenase-1 (HMOX1) mRNA expression as a measure of antioxidant defence activity when free iron is available. Importantly, we observed that in the FPN-low cell lines UKE-1 and KCL22 levels of HMOX1 mRNA were not significantly elevated, while the MV411 cell line (FPNlow) was highly upregulated for HMOX1 (pink dot in Fig. 1h ) when compared with untreated cells. Similarly, levels of glutamate-cysteine ligase catalytic subunit (GCLC) mRNA were unchanged except for the same cell line, MV411, which was also elevated in mRNA expression (Fig. 1h) . Expression of solute carrier family 7 member 11 (SLC7A11), the cystine glutamate antiporter, was also significantly upregulated in FPN-low cell lines with ferumoxytol administration. Overall, the cell lines MV411 and KCL22 were the most sensitive to ferumoxytol administration in terms of cell viability and stress gene response (Fig. 1g,h ), suggesting that these cells are vulnerable to ROS accumulation driven by ferumoxytol. Additional gene expression levels relating to iron management, antioxidant production and inflammation were also evaluated for the leukaemia cell lines and are provided in Supplementary Figs. 6-8. mRNA of inflammation markers such as interleukin (IL)-1β, IL-6 and tumour necrosis factor (TNF)-α revealed no significant incr ease upon ferumoxytol administration (by qRT-PCR, Supplementary  Fig. 7 ). Principal component analysis ( Supplementary Fig. 8 ) revealed that increases in HMOX1 are anticorrelated with SLC40A1 (FPN), with antioxidant genes being the strongest contributors to each principal component. Measuring cytosolic and mitochondrial ROS at 24 h and 48 h post ferumoxytol administration (Fig. 1i) confirmed FPN-low cell lines were most affected, and the greatest increases in either cytosolic or mitochondrial ROS (green and pink dots in Fig. 1g ) correspond to the lowest-viability cell lines. Flow cytometry fluorescence intensity plots in Supplementary  Fig. 9 show the degree of ROS shift. Protection of FPN-low cell lines against ROS using the antioxidant N-acetyl cysteine confirmed that oxidation by ferumoxytol contributes to cell stress and reduced viability ( Supplementary Fig. 10 ). Measured secreted cytokines IL-1β, IL-6 and TNF-α by flow had below-detection-limit levels for the AML cell lines tested and no significant increases were observed after ferumoxytol administration for 24 h ( Supplementary  Fig. 11 ), in line with the lack of cytokine mRNA levels as measured by qRT-PCR.
Ferumoxytol as an anti-leukaemic therapy
In searching for leukaemia mouse models to evaluate the in vivo effect of ferumoxytol, we mined the microarray data of the blast crisis leukaemia (bcCML) model, which consists of cooperative oncogenes BCR-ABL (GFP) and NUP98-HOXA9 (YFP) 18, 19 and found that bcCML cells (GFP ). This acute leukaemia model has similar target organs, aggressiveness and refractory behaviour to chemotherapeutics as human AML. We tested the effect of ferumoxytol, and used the standard-of-care drug for AML, cytarabine (ara-C) as a control. C57BL/6 female mice were transplanted with leukaemic cells bearing BCR-ABL (GFP)/NUP98-HOXA9 (YFP) oncogenes 18 . Mice were bled and monitored for the percentage of leukaemic blasts in peripheral blood and randomized into four different cohorts (n = 7) when the blast burden in the blood exceeded 0.1%. Cohorts were administered with saline, ara-C (40 mg kg −1 ) or ferumoxytol low at 3 mg kg −1 or high at 6 mg kg ). Ara-C was administered by intraperitoneal injection (i.p.) and saline and ferumoxytol were administered intravenously (i.v.) twice a week, as indicated in Fig. 2a . The burden of leukaemic blasts was monitored every week until the onset of morbidity, at which time all of the cohorts were euthanized and evaluated for tumour burden in the peripheral blood, bone marrow and spleen. In comparison with the saline control group there was a significant reduction in the percentage of leukaemic blasts populations in peripheral blood, bone marrow and spleen of mice only treated with ferumoxytol 6 mg kg −1 ( Fig. 2b-e ). Splenomegaly is a feature of blast infiltration and disease progression. We found that ferumoxytol radiolabelled with the positron emission tomography radiotracer 89 Zr could identify spleen and liver margins for facile quantification of spleen volume ( Supplementary  Fig. 12a ). We found that the spleen weight of animals treated with ferumoxytol 6 mg kg −1 was overall lower, as shown by the lower spleen index (spleen weight/total body weight) (Fig. 2f) , indicating decreased disease burden. These data demonstrate that ferumoxytol at 6 mg kg −1 is able to induce an anti-leukaemic effect in peripheral blood, bone marrow and spleen.
Next, we evaluated the effect of ferumoxytol, administered via i.p. injection, on the overall burden and survival of mice. The mice were treated with saline or ferumoxytol at 6 mg kg −1 three times a week, while monitoring the peripheral blood burden weekly until death (Fig. 2g) . Ferumoxytol clearly and significantly reduced the leukaemic blast burden through 21 days in peripheral blood + cells are represented as low (blue) and high (red) to evaluate the iron content at 24 h (n = 3 cell lines for FPN-low and FPN-high) determined by inductively coupled plasma mass spectrometry (f) and cell survival (g), represented by cell counts at 24 h and 48 h after exposure to ferumoxytol (FH) or PBS (n = 3 per group and time point). The green and pink dots in g-i represent KCL22 and MV411, respectively. h, Levels of gene expression for HMOX1, GCLC and SLC7A11 relative to untreated samples (n = 3 technical replicates per cell line, n = 3 cell lines (shown with s.e.m.) for FPN-low and FPN-high lines (n = 6 cell lines total). i, Cytosolic and mitochondrial staining for ROS using H 2 DCFDA and MitoSox, respectively, reveal elevated ROS levels in FPN-low lines (n = 2 independent measurements per cell line (n = 3 cell lines per FPN-low or FPN-high group) per time point). S.e.m. determined based on cell lines in each FPN-low or FPN-high group as biological replicates. Each symbol represents a sample, the bar represents the mean and the error bar represents s.e.m. An ordinary one-way analysis of variance (ANOVA) was used for e. A two-tailed unpaired t-test was used for f-h. Numbers over bars denote P-values. Flow experiments were performed once with corresponding controls (unstained, isotype or fluorescence minus one). qRT-PCR data were also obtained once for each cell line and gene in triplicate.
( Fig. 2h ) and led to a significant increase in median survival time (25 days ferumoxytol 6 mg kg −1 , 17 days saline) (Fig. 2i) . A similar survivability study with 89 Zr-ferumoxytol confirmed the increase in median survivability ( Supplementary Fig. 13 ). These findings demonstrate an anti-leukaemia effect with ferumoxytol administration alone, as well as prolonged overall survival. Moreover, these data suggest that ferumoxytol can be a potential therapeutic against leukaemia cells and be tolerated by two different routes of administration.
Patient-derived xenografts respond to ferumoxytol
With the observed therapeutic effect in vivo using the murine bcCML model, we next aimed to determine the therapeutic efficacy of ferumoxytol in AML-PDXs using human primary AML cells with either FPN-high or -low expression (mRNA expression relative to nBM CD34 + cells). Established AML-PDXs were treated twice a week (Fig. 3a) , and FPN-low AML-PDXs in three different AMLPDXs showed a reduction in burden ( Fig. 3b and Supplementary  Fig. 14) . In contrast, the FPN-high AML-PDX was unaffected. saline n = 10 mice, ferumoxytol n = 10 mice; day 14: saline n = 7 mice, ferumoxytol n = 10 mice; day 21: saline n = 3 mice, ferumoxytol n = 8 mice). Experiment performed once. i, Kaplan-Meier survival plot for mice treated with saline or ferumoxytol (n = 10 mice per group). Each symbol represents a mouse, the bar represents the mean, and the error bar represents s.e.m. Unpaired two-tailed t-tests were used to compare saline and ferumoxytol 6 mg kg −1 in c-f. Experiment performed twice and replicate curve reported in Supplementary Fig. 13 . Multiple t-tests for 7, 14 and 21 days assuming different s.d.s were used for h with a false discovery rate of 5% using a two-stage set-up method. The comparison of survival curves in i was performed using a log-rank Mantel-Cox test. Numbers over bars denote P-values.
Importantly, normal haematopoietic cells, established with CD34
+ cord blood and with high FPN levels, remained unaffected during ferumoxytol administration. In summary, ferumoxytol selectively induced an anti-leukaemic effect in FPN-low AML-PDXs without affecting FPN-high AML-PDXs or cord blood.
Ferumoxytol consists of two iron oxidation states capable of undergoing the Fenton reaction, so we sought to determine the native oxidative capacity of ferumoxytol in human cells from FPNlow-expression AML-PDXs. HMOX1 expression is a measure of antioxidant defence activity when free iron is available, so HMOX1 activity following ferumoxytol administration was used as a readout of cellular oxidative stress. We detected in patient samples that ferumoxytol treatment resulted in a two-to sixfold increase in HMOX1 transcript levels (Fig. 3c) , suggesting that ferumoxytol increases the levels of ROS in these cells. Further cell-free tests for peroxidase activity and ROS generation were done with ferumoxytol ( Supplementary Figs. 15-17 ). Peroxidase and ROS activity rates were consistent with an enzymatic or catalytic process requiring ferumoxytol and exceeded the ROS production of FeCl 3 after 12 min. In the absence of exogenous iron, primary AML samples expressing low FPN constitutively expressed higher HMOX1 with accumulated iron, suggesting that these cells were uniquely susceptible for further toxic ROS accumulation. The production of ROS from ferumoxytol demonstrates that ferumoxytol can fuel an oxidative overload in cells with significantly low FPN expression. As such, these findings encourage the use of ferumoxytol as a cancer therapeutic, where ferumoxytol selectively targets leukaemia cells with low FPN. The selective toxicity of ferumoxytol is focused on AML samples with low FPN expression while normal stem cells and tissue with higher FPN expression are spared. This opens a promising avenue to aid in the eradication of leukaemia (and potentially other tumour cells) cells with specific deficient iron export features in combination with existing standard-of-care therapy.
Oxidative effect of ferumoxytol on FPN-low leukaemias
Our previous work with AML therapy has shown that PTL can inhibit NF-κB, deplete glutathione and thus induce proapoptotic cell death 7 . Separately, previous studies have highlighted the importance of FPN expression in identifying more aggressive cancers with poorer prognosis 22 . Here, we report that the majority of leukaemia cell lines as well as primary AML patient samples are FPN-low (Fig. 1a-d) . FPN expression decreased even further in leukaemic stem and progenitor cells (Fig. 1e) , revealing that the chemoresistant stem cell population that results in disease relapse could be vulnerable. We have shown that administration of the FDAapproved iron oxide nanoparticle ferumoxytol leads to elevated iron content (Fig. 1f) , resulting in reduced viability only in FPN-low leukaemic cell lines ( Fig. 1g and Supplementary Fig. 4 ). We found ferumoxytol to increase oxidative stress and antioxidant synthesis genes with no change in inflammation markers at 24 h ( Supplementary  Figs. 7 and 11 ). Ferumoxytol contains both ferrous and ferric forms of iron, which, in the presence of endogenous cellular peroxide 23 , can undergo the Fenton reaction 24 , yielding either a hydroxide radical or a hydroperoxide radical from the ferrous and ferric forms, respectively. As ferumoxytol contains both oxidation states, ferumoxytol serves as a catalytic radical reactor when placed into a peroxideproducing environment such as a cancer cell. Traditional atomic iron is well regulated, but ferumoxytol is a carboxymethyl dextrancoated iron oxide nanoparticle containing over 5,000 iron atoms and enters the cell through endocytosis 25 . We have observed that the administration of ferumoxytol to FPN-low-expressing leukaemia cell lines increases cytosolic and mitochondrial ROS (Fig. 1i) , in agreement with the reduced viability observed (Fig. 1g) . By administering ferumoxytol to FPN-low AML samples, the reduction in viability is driven in part by the increased iron retention driving the Fenton reaction with ferumoxytol together with the exhaustion of antioxidants by increased ROS production in FPN-low lines.
This ability to drive FPN-low AML lines into death with ferumoxytol represents a paradigm shift in cancer therapy achieved with an FDA-approved drug for anaemia. In vivo, using a blast crisis CML mouse model with FPN-low expression in leukaemic blasts, we were able to observe the reduction of leukaemic blasts in peripheral blood, bone marrow and spleen, with a significant reduction in spleen burden (Fig. 2e,f) that could not be achieved with ara-C during induction therapy. Ferumoxytol biodistribution has been demonstrated previously, with radiolabelled ferumoxytol being found in the liver, spleen and mesenteric lymph nodes 26 . Most importantly, administration of ferumoxytol alone extends the survival of mice ( Fig. 2h and Supplementary Fig. 13 ). In blast crisis CML, infiltration of leukaemic progenitors into the spleen and liver presents a challenge, leading to enlarged spleen and ultimately organ failure 27 . Here, ferumoxytol's biodistribution may be advantageous as i.v. administration results in rapid liver and spleen accumulation within 1 h 26 . As the low FPN expression is a feature of the leukaemia cells, ferumoxytol could provide directed therapy in these organs.
Furthermore, the effectiveness of ferumoxytol against FPN-low leukaemia cells was extended to patient-derived primary AML xenografts. In vivo, ferumoxytol administration showed a significant reduction in burden for FPN-low-expressing AML-PDXs (Fig. 3b) . Here, the reduction occurred in a mouse model lacking an adaptive immune system, and we found a sixfold increase in HMOX1 transcript levels from human leukaemic cells obtained from AML-PDXs after administering ferumoxytol, suggesting an increase in ROS in AML cells (Fig. 3c) . Recent work has demonstrated the anti-tumour efficacy of ferumoxytol through the polarization of tumour-associated macrophages into the tumour-inhibiting M1 phenotype in a murine lung cancer model 28 . Here, we show the anti-leukaemia effect with ferumoxytol is also observed in an immunocompromised system lacking functional macrophages and ferumoxytol treatment does not induce common inflammatory cytokines. As macrophage repolarization or immune stimulation does not play a significant role, the biological effect of ferumoxytol described here is entirely different and based on the expression of FPN within the cancer cells. We know from the Fenton reaction that iron in the presence of peroxide generates ROS, without consuming the iron and allowing a catalytic process. We also observed that ferumoxytol produces ROS at a greater rate than free iron after 12 min and maintains a steady production rate. We propose that oxidative ferrotherapy is effective due to the inability of cells with low FPN expression to efficiently export the abundance of available iron in the form of ferumoxytol (Fig. 4) , which generates ROS in excess of the cell antioxidant capacity. As ferumoxytol has been used widely for anaemia in patients with chronic kidney disease and recently approved for all patients with anaemia 29 , it is feasible to translate ferumoxytol to a therapeutic intervention for AMLs with low FPN expression.
Conclusions
The low iron export phenotype in leukaemias has provided a window for a clinical nanoparticle to exert toxic ROS stress and provide therapeutic benefit. By delivering an iron oxide nanoparticle that is internalized in a different way than molecular iron, ferumoxytol can supply a ROS source to leukaemias in a manner not governed by traditional iron regulation. Further studies will be needed to identify additional molecular features linked to the response to ferumoxytol by leukaemic cells with low FPN to unravel synergistic therapeutic strategies. Combinations with existing FDA-approved drugs that produce ROS may most immediately open avenues to eradicate leukaemias with a low iron export phenotype. This knowledge will help rationally combine ferumoxytol with yet to be approved drugs such as PTL, which have already been reported to exhibit an anti-leukaemic effect through ROS generation. Because no therapy for leukaemias with specific deficient iron export has been developed yet, this would be an important advance in the treatment of AML. More broadly, these findings recommend exploring the use of nanoparticle iron against other cancers with a low iron export phenotype as an oxidative ferrotherapy.
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Methods
Primary samples. Primary AML samples and bone marrow from healthy donors were obtained with informed consent, abiding by ethical compliance requirements established and approved by Institutional Review Boards from Weill Cornell Medical College-New York Presbyterian Hospital and from the University of Rochester Medical Center. Primary cryo-preserved AML samples were thawed and cultured as previously described 4 . Enrichment of CD34 + cells was performed using an indirect CD34 Microbead Isolation Kit (Miltenyi Biotec), according to the manufacturer's instructions.
Cell lines. Leukaemia cell lines were obtained from the American Type Culture Collection or DSMZ (German Collection of Microorganisms and Cell Cultures), and all cell lines were authenticated and tested for mycoplasma. Cells were cultured in Iscove's modified Dulbecco's medium (Life Technologies) supplemented with 10-20% FBS (Gemini Bio-Products) and 1% penicillin/streptomycin Life Technologies). N-acetyl cysteine was obtained from Millipore.
Analysis of CD68 expression. Leukaemia cell lines were blocked in FACS buffer (PBS + 0.5% FBS) containing human Fc block (BD Biosciences; 564220) for 20 min at room temperature. Cells were fixed, permeabilized using the BD Cytofix/ Cytoperm fixation/permeabilization kit (BD Bioscience) and later stained with anti-human CD68-PECy7 (BioLegend; 333816). Sample acquisition was performed on a BD LSR II flow cytometer and the mean fluorescence intensities were calculated using FlowJo 9.3 software for Mac OS X (TreeStar).
Uptake and cytotoxic effect of ferumoxytol-Cy5.5 labelled. To evaluate the cellular uptake of ferumoxytol-Cy5.5 labelled, leukaemia cell lines were seeded at a density of 5 × 10 4 cells per ml. Cells were treated with ferumoxytol-Cy5.5 0.1 mg ml −1 and incubated at 37 °C for 6 h. The cells were then washed with FACS buffer and stained with DAPI 1 µg ml
. Samples were evaluated by flow cytometry using a BD LSR II cytometer. The percentage of cells positive for ferumoxytolCy5.5 was determined relative to the vehicle control cells.
To test the effect of ferumoxytol-Cy5.5 on cell viability, cells were seeded as previously described and treated every 24 h with ferumoxytol-Cy5.5 0.1 mg ml
and incubated at 37 °C. Staining with DAPI 1 µg ml −1 and sample recording were performed at the indicated times. At least 1 × 10 4 events per condition were recorded on a BD LSR II flow cytometer. Cells that were negative for DAPI were scored as viable, and the viability of treated cells was normalized to control cells (PBS only). ROS-dependent cell death was determined by pre-treatment of the cells with N-acetyl-cysteine 1 mM l −1 for 2 h before ferumoxytol-Cy5.5 exposure. Each in vitro assay was conducted in triplicate and repeated at least three times. Cell viability was expressed as a percentage of ferumoxytol-Cy5.5 treated cells relative to control cells.
Measurement of cytosolic and mitochondrial ROS levels. Cytosolic ROS changes were monitored using 5-(and 6-)chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA, C6827 Invitrogen, Molecular Probes) and the mitochondrial ROS changes were assessed using the MitoSox Red mitochondrial superoxide indicator (MitoSox, M36008 Invitrogen, Molecular Probes). Both fluorescent dyes were prepared as a 5 mmol l −1 solution in DMSO and stored at −20 °C. According to the manufacturer's instructions, leukaemia lines were co-stained with CM-H2DCFDA and MitoSox for 30 min at 37 °C before the end of the incubation with ferumoxytol-Cy5.5 for the indicated treatment times. The fluorescence shift indicative of cytosolic or mitochondrial ROS change was analysed on a BD LSRII flow cytometer. The cytosolic or mitochondrial ROS levels were expressed as fold change determined by calculating the fold change in ferumoxytol-Cy5.5-treated cells relative to the ROS levels in control cells.
Nanoparticles. Nanoparticles in the form of ferumoxytol (Feraheme; AMAG Pharmaceuticals) were acquired from the MSKCC pharmacy. Ferumoxytol doses used for in vivo administration were diluted from 30 mg ml −1 stock into sterile 0.9% NaCl bottles for dosing for a final concentration of 6 mg kg −1 delivered in 200 μl total volume. A radiolabelled version of ferumoxytol was made using the chelate-free heat-induced radiolabelling method 26 .
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Zr was produced on the MSKCC cyclotron and purified as zirconium oxalate. Positron emission tomography was performed on a Siemens Inveon acquisition workplace v 2.0.0.1050 and Inveon acquisition workstation v 4.1. Cy5.5-ferumoxytol was synthesized as previously described 30 .
Oxidative ferrotherapy assessment. Peroxidase activity was performed using ferumoxytol in the presence or absence of peroxide and horseradish peroxidase. The oxidative power of ferumoxytol was determined by chemiluminescence with 1.25 mg ml −1 luminol and titrations of ferumoxytol or iron equivalent up to 1,000 µg Fe per well. Radiances were measured immediately and through 30 min of luminol mixture addition on an IVIS Spectrum imager using an open filter (n = 8 per group).
Iron determination. Intracellular iron was determined by a complete digest of the cell with iron content determined by inductively coupled plasma mass spectrometry. The iron was reported in mg per mg of protein, as determined before sample digestion by bicinchoninic acid for determination of total protein by absorbance compared to known amounts of bovine serum albumin.
Animal models. Syngeneic model. C57BL/6 mice (6-8 weeks old) were purchased from Jackson Laboratories. Mice were housed in a temperature-and humiditycontrolled animal facility with a 12 h light/dark cycle and had free access to water and food. The experimental procedures were approved by the Institutional Animal Care and Use Committee of Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center. Murine bcCML was generated by the injection of spleen cells (40 × 10 4 cells per mouse) carrying BCR-ABL/NUP98-HOXA9 oncogenes generously provided by C.T. Jordan (University of Colorado School of Medicine) 19, 31 . When around 0.1% of leukaemic blasts were detected in peripheral blood, mice were randomly separated into the study cohorts. Animals that exceeded 2 s.d. from the mean per cent of leukaemic blasts in peripheral blood were excluded from the study. Ten mice per cohort were used for survival studies to allow for 10% resolution. Mice were randomly assigned to treatment groups based on housing cage, with two cages per group. Investigators were not blinded to the therapy that mice were receiving. Ferumoxytol was administered by i.v. (2× per week) or i.p. (3× per week) injection. Ara-C was administered i.p. for four consecutive days. The bodyweight and leukaemic burden were monitored weekly in peripheral blood. Animals were euthanized at the indicated time points or at signs of distress. Peripheral blood, bone marrow and spleen were harvested to evaluate leukaemic burden.
Xenotransplants. Non-obese diabetic/severe combined immunodeficient (NOD/SCID) or NOD/SCID IL2Rgamma null (NSG) mice were obtained from the Jackson Laboratories. Mice were sub-lethally irradiated with 200 rad using a RadSource-2000 X-ray irradiator (RadSource) the day before transplantation. Primary AML samples or cord blood CD34 + cells were injected via the tail vein (2-5 million cells for AML; 300,000 for CD34
+ cord blood) in a final volume of 0.2 ml of FACS buffer (PBS with 0.5% FBS). After human cell engraftment was confirmed by evaluating the peripheral blood (3-4 weeks), treatment with ferumoxytol (5 mg kg Leukaemia burden evaluation in the syngeneic model. Leukaemia burden evaluation in the syngeneic model was performed by evaluating the percentage of GFPor GFP-and YFP-positive cells in peripheral blood, bone marrow or spleen. Peripheral blood was processed by red blood cell lysis, and bone marrow and spleen were harvested as previously described 18 .
Leukaemia burden evaluation in xenograft model. To assess human cell engraftment, bone marrow was harvested at the indicated time point. Cells were stained with anti-human CD45-APCH7 (hCD45, 2D1) and anti-mouse CD45-PECy5 (mCD45; 3OF11, BioLegend). Human cells were determined by evaluating the percentage of hCD45 + mCD45 − cells. Cells were evaluated in a BD LSR II analytical flow cytometer.
Inflammation and cytokine production. Human cytokines IL-1β, IL-6 and TNF-α produced by human AML cell lines were determined using two cytokine detection kits (LEGENDplex Human Th Panel (13-plex) with V-bottom Plate (BioLegend, #740722) or LEGENDplex Human Inflammation Panel (13-plex), BioLegend, #740118). The culture supernatants from AML cell lines were collected after 24 h of ferumoxytol treatment and later evaluated via flow cytometry with the above kits. Analysis was later performed using FlowJo 9.3 software for Mac OS X (Tree Star).
qRT-PCR. Total RNA was isolated from leukaemic cell lines, primary human samples or mouse tissues using Direct-zol (Zymo Research) according to the manufacturer's protocol. Reverse transcription reaction was performed using the VILO SuperScript IV kit (Thermo Fisher Scientific). Amplification for the genes of interest was performed using the PCR Master Mix (Thermo Fisher Scientific). Triplicate samples per condition were evaluated on a StepOnePlus Real-Time PCR (ABI-USA) instrument using absolute quantification settings with a sample volume of 20 µl and 40 amplification cycles. Differences in gene expression levels were compared to the ABL1 internal reference and represented as relative to normal BM CD34 + cells using the 2 -ΔΔCt method. ABL1 was assayed using Hs01104728_m1, SLC40A1 (FPN) was assayed using Hs00205888_m1, and HMOX1 was assayed using Hs0110250_m1. All TaqMan probes were obtained from Thermo Fisher Scientific; a complete list of probes used is provided in Supplementary Table 4 .
Statistical analysis. All data are presented as mean ± s.e.m. and statistical analysis and graphs were performed using GraphPad Prism software (GraphPad Software). For statistical analyses the data were analysed by one-way ANOVA followed by Tukey post-hoc test. For two groups comparisons, significance was determined with the two-tailed unpaired Student's test. Kaplan-Meier curves were determined with a log-rank Mantel-Cox test. Principal component analysis was done using R-studio with R version 3.5.1.
Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this Article.
Data availability
The data that support the plots within this paper and other findings of this study are available from the corresponding author upon reasonable request. 
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Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
The data that support the plots within this paper and other findings of this study are available from the corresponding author upon reasonable request.
